Tower Urology of Los Angeles is current enrolling for the following Clinical Trials:
Looking for an alternative to Cystectomy?
If your bladder cancer persisted or returned following BCG treatment, ask your doctor about our clinical research study. The study will evaluate whether the investigational drug is safe and effective for patients with bladder cancer that has not yet spread to the bladder muscle and who have previously received BCG treatment. If your cancer returned or continued to grow despite treatment with BCG, then cystectomy may be one of the options considered next. This clinical study may be another option.
Vicinium Study in Bladder Cancer
The VISTA study is a clinical research study for Viventia Bio’s investigational drug, Vicinium™, being developed for nonmuscle invasive bladder cancer. This study is designed to learn whether Vicinium™ is safe and effective for patients with bladder cancer that has not yet spread to the bladder muscle and who have previously received BCG treatment. More than 100 patients with this type of bladder cancer have been treated with Vicinium™ in a prior Phase 1 and a Phase II study.
Interstitial Cystitis with Hunner’s Lesion
- Allergan: A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS 400 mg in Females with Interstitial Cystitis with Hunner’s Lesion
Interstitial Cystitis/ Bladder Pain Syndrome
- Allergan: A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS 400 mg in Females with Interstitial Cystitis/Bladder Pain Syndrome
AxuminTM (fluciclovine F 18)
The Tower Urology Research Institute is excited to announce an actively recruiting phase III clinical trial for PSA‐persistent or PSA‐recurrent prostate cancer after curative‐intent primary therapy with either and negative or equivocal findings on standard‐of‐care imaging.
Conventional imaging such as CT, bone scans and MRI have limited sensitivity in this setting especially with PSA levels 2.0 ng/ml. AxuminTM (fluciclovine F 18) injection is a novel molecular imaging agent indicated for use in positron emission tomography (PET/CT) imaging to identify suspected sites of prostate cancer recurrence in men with elevated PSA following prior
treatment with radiation or surgery.
It is the first FDA‐approved F18 PET imaging agent for use in patients with suspected recurrent prostate cancer. Although the agent received FDA priority review clearance in May and will be commercially available this fall, our team in collaboration with RadNet Oncology Radiology and Cancer Research Collaboration are currently the exclusive actively accruing site in Los Angeles for this very promising and exciting PET agent. Our initial experience with this agent has been very encouraging.
TRUMPET REGISTRY STUDY
Do you or someone you care about have Prostate Cancer? If so, starting new treatment for Prostate cancer?
Is PSA rising again after Hormone Treatment? Please consider taking part in the TRUMPET Registry Study.
What is the TRUMPET Registry Study?
It is an observational Study of patients with Castration Resistant Prostate Cancer (CPRC) in the United States. The primary objectives are to describe patterns of care, disease assessment methods, treatment decisions, physician referrals and CRPC patient characteristics associated with these.
Who can join the TRUMPET Registry Study?
Men whose Prostate Cancer fits the following may be able to join:
- Has progressed despite treatment with hormonal therapy or with Castration Resistant Prostate Cancer
- Cancer remains in the prostate or spreads beyond
- Initiates the first active course of anti-cancer treatment such as anti-androgens, androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy. May be enrolled within 45 days from the time of treatment initiation.
A clinical research study for men with Prostate Cancer is now enrolling!
If you have been diagnosed with prostate cancer you may be interested to learn about the ATLAS clinical research study, which is being conducted in patients to determine if an investigational medication combined with Gonadotropin Releasing Hormone agonist (Gn-RHa) improves treatment with radiation therapy (RT).
You may be eligible to participate if:
- You have been diagnosed with prostate cancer
- You have not received treatment except GnRHa
- You have radiation therapy planned for your treatment
Additional criteria will be reviewed at the screening visit to determine if your condition meets all requirements for the study.
Eligible study participants will be provided with study medication and study-related medical care at no cost during the study.
You may be eligible for a clinical trial studying a new investigational drug option. This clinic will be conducting a clinical trial on a new investigational drug for prostate cancer.
For this trial we are looking for males who have been treated for or who have had surgery for prostate cancer and the cancer has metastasized.
Ask your doctor if you’re eligible to participate in CHURCHILL PHARMA Clinical Trial.
Your participation will bring scientists closer to finding new treatments and cures.
Join a research study to evaluate the safety and efficacy of ALLN-177
You must qualify for the study through a screening process.
- If you qualify, you will be enrolled to receive study-related medical care including monitoring through blood tests and urine collections
- You will be asked to follow your usual eating habits throughout the study
- You will receive financial compensation for your participation in the study
- You will be helping the study sponsor learn if use of the drug demonstrates lowering of oxalate in the urine
Who can join the studies?
- Patients with a history of a large amount of oxalate in the urine (hyperoxaluria)
- Are age 18 and older
- Urine oxalate level 50 mg/day or higher during screening
- Not pregnant and must use acceptable form of birth control during the study
- No current significant diseases, cancer or conditions that may exclude you from the study Cannot be on current investigational drug
Your study physician will review all eligibility criteria with you to determine if ALLENA study is appropriate for you
Low Testosterone can leave you feeling out of tune.
Some men do not have adequate blood levels of testosterone. While some men don’t notice a difference, many others experience symptoms of the LOW TESTOSTERONE levels such as decreased energy, reduced sex drive, and increased body fat.
If you’re struggling with low testosterone, learn more about the inTUne research study.
To pre-qualify for the inTUne study, you must:
- Be male, 18 to 65 years of age
- Have been diagnosed with or have symptoms of low testosterone
- Have not received prior testosterone treatment or be willing to stop taking current treatment for low testosterone
All study-related visits, tests and medications will be provided to participants at no cost. In addition, reimbursement for study-related time and travel may be provided.
You will be closely monitored while in this study. Researchers for this study are required to follow a protocol, which explains all study procedures in detail. An independent review board is responsible for participant safety and it has reviewed and approved this protocol.
Download the full Tower Urology Clinical Trials – Enrolling Studies 2016 or the Low Testosterone inTUne study.
Select and Register for a Tower Urology Clinical Trial
Tower Urology is located in Los Angeles at:
Cedars-Sinai Office Towers
8635 West 3rd Street
Suite 1 West
Los Angeles, CA 90048